Identification

Name
Neomycin
Accession Number
DB00994  (APRD00013)
Type
Small Molecule
Groups
Approved, Vet approved
Description

A component of neomycin that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). Neomycin is a bactericidal aminoglycoside antibiotic that binds to the 30S ribosome of susceptible organisms. Binding interferes with mRNA binding and acceptor tRNA sites and results in the production of non-functional or toxic peptides.

Synonyms
  • Fradiomycin
  • Kaomycine
  • Neomicina
  • Vonamycin
External IDs
Caswell No. 595 / USAF CB-19
Product Ingredients
IngredientUNIICASInChI Key
Neomycin palmitate3I9J454G9F55298-68-5Not applicable
Neomycin sulfate057Y6266931405-10-3Not applicable
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mycifradin Sulfate Oral SolutionSolution125 mgOralPharmacia & Upjohn Inc1957-12-312000-08-02Canada
Mycifradin Sulfate Tablets 0.5 GmTablet500 mgOralPharmacia & Upjohn Inc1953-12-312000-08-02Canada
Myciguent OintmentOintment.5 %TopicalUpjohn1951-12-311998-08-12Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Neo-FradinSolution87.5 mg/5mLOralX Gen Pharmaceuticals, Inc.2002-05-232012-12-31Us
Neomycin SulfateTablet500 mg/1OralLannett Company, Inc.2016-06-10Not applicableUs
Neomycin SulfateTablet500 mg/1OralGolden State Medical Supply2011-01-032018-10-11Us51991 0738 01 nlmimage10 951b4ada
Neomycin SulfateTablet500 mg/1OralTeva Pharmaceuticals USA, Inc.1990-09-30Not applicableUs00093 1177 01 nlmimage10 4f2b27c9
Neomycin SulfateTablet500 mg/1OralHi-Tech Pharmacal2010-03-12Not applicableUs50383 0565 10 nlmimage10 1f460f80
Neomycin SulfateTablet500 mg/1OralEci Pharmaceuticals Llc2016-01-162016-07-10Us
Neomycin SulfateTablet350 mg/1OralBreckenridge Pharmaceutical, Inc.2011-01-032020-04-30Us
Neomycin SulfateTablet500 mg/1OralX Gen Pharmaceuticals, Inc.2010-03-12Not applicableUs
Neomycin SulfateTablet500 mg/1OralMajor2009-09-142012-10-01Us
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AntibioticOintment3.5 mg/1gTopicalMorales Distributors, Inc.2012-09-25Not applicableUs
AntibioticOintment3.5 mg/1gTopicalPro Mex Llc2013-12-05Not applicableUs
AntibioticOintment3.5 mg/1gTopicalKareway Product, Inc.2011-08-11Not applicableUs
Antibiotic OintmentOintment3.5 mg/1gTopicalNeopharm Co., Ltd2010-08-26Not applicableUs
BaclezeneCream5 mg/0.9gTopicalCurazene, Llc2014-06-19Not applicableUs
Family Care AntibioticOintment3.5 mg/1gTopicalUnited Exchange Corporation2012-11-302017-12-26Us
Family Care AntibioticOintment3.5 mg/1gTopicalUnited Exchange Corporation2017-12-29Not applicableUs
Family Care Triple Antibiotic Pain ReliefOintment3.5 mg/1gTopicalUnited Exchange Corporation2012-02-07Not applicableUs
First Aid Only Antibiotic Neomycin SulfateOintment3.5 mg/1gTopicalAcme United Corporation2017-12-18Not applicableUs
NeomycinOintment3.5 mg/1gTopicalHoneywell Safety Products USA, Inc2010-03-31Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
10 Person ANSINeomycin sulfate (5 mg/1g) + Acetaminophen (325 mg/1) + Acetylsalicylic acid (325 mg/1) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (0.40 mL/100mL) + Benzocaine (6 mL/100mL) + Ethanol (60 mL/100mL) + Ibuprofen (200 mg/1) + Lidocaine (0.5 1/100g) + Polymyxin B Sulfate (5000 [iU]/1g) + Water (98.6 mL/100mL)KitGenuine First Aid2010-04-24Not applicableUs
25 Person ANSINeomycin sulfate (5 mg/1g) + Acetaminophen (325 mg/1) + Acetylsalicylic acid (325 mg/1) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (0.40 mL/100mL) + Benzocaine (6 mL/100mL) + Ethanol (60 mL/100mL) + Ethanol (62 g/100g) + Ibuprofen (200 mg/1) + Isopropyl Alcohol (70 mL/100mL) + Lidocaine (0.5 g/100g) + Polymyxin B Sulfate (5000 [iU]/1g) + Water (98.6 mL/100mL)KitGenuine First Aid2010-04-25Not applicableUs
4042 First Aid KitNeomycin sulfate (3.5 mg/1g) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Lidocaine hydrochloride (0.5 g/100g) + Polymyxin B Sulfate (5000 [iU]/1g) + Povidone-iodine (10 mg/1mL)KitHoneywell Safety Products USA, Inc2018-11-21Not applicableUs
4044 First Aid KitNeomycin sulfate (3.5 mg/1g) + Benzalkonium chloride (0.13 g/100g) + Lidocaine hydrochloride (0.5 g/100g) + Povidone-iodine (10 mg/1mL)KitHoneywell Safety Products USA, Inc2018-11-21Not applicableUs
4045 First Aid KitNeomycin sulfate (3.5 mg/1g) + Benzalkonium chloride (0.13 g/100g) + Lidocaine hydrochloride (0.5 g/100g) + Povidone-iodine (10 mg/1mL)KitHoneywell Safety Products USA, Inc2018-11-21Not applicableUs
4049 First Aid KitNeomycin sulfate (3.5 mg/1g) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (1.3 mg/1mL) + Lidocaine hydrochloride (0.5 g/100g)KitTopicalHoneywell Safety Products USA, Inc2018-11-29Not applicableUs
4050 First Aid KitNeomycin sulfate (3.5 mg/1g) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Lidocaine hydrochloride (0.5 g/100g) + Polymyxin B Sulfate (5000 [iU]/1g) + Povidone-iodine (10 mg/1mL)KitHoneywell Safety Products USA, Inc2018-11-21Not applicableUs
4051 First Aid KitNeomycin sulfate (3.5 mg/1g) + Benzalkonium chloride (0.13 g/100g) + Ethanol (0.5 mL/1mL) + Isopropyl Alcohol (0.7 mL/1mL) + Lidocaine hydrochloride (20 mg/1mL) + Lidocaine hydrochloride (0.5 g/100g)KitHoneywell Safety Products USA, Inc2018-11-21Not applicableUs
4052 First Aid KitNeomycin sulfate (3.5 mg/1g) + Benzalkonium chloride (0.13 g/100g) + Ethanol (0.5 mL/1mL) + Isopropyl Alcohol (0.7 mL/1mL) + Lidocaine hydrochloride (0.5 g/100g) + Lidocaine hydrochloride (20 mg/1mL)KitHoneywell Safety Products USA, Inc2018-11-21Not applicableUs
50 Person ANSINeomycin sulfate (5 mg/1g) + Acetaminophen (325 mg/1) + Acetylsalicylic acid (325 mg/1) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (0.40 mL/100mL) + Benzocaine (6 mL/100mL) + Ethanol (60 mL/100mL) + Ethanol (62 g/100g) + Ibuprofen (200 mg/1) + Isopropyl Alcohol (70 mL/100mL) + Lidocaine (0.5 g/100g) + Polymyxin B Sulfate (5000 [iU]/1g) + Water (98.16 mL/100mL)KitGenuine First Aid2010-06-02Not applicableUs
International/Other Brands
Myacyne / Mycifradin / Myciguent / Neo-Rx / Neobiotic / Nivemycin
Categories
UNII
I16QD7X297
CAS number
1404-04-2
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Topical uses include treatment for superficial eye infections caused by susceptible bacteria (used in combination with other antiinfectives), treatment of otitis externa caused by susceptible bacteria, treatment or prevention of bacterial infections in skin lesions, and use as a continuous short-term irrigant or rinse to prevent bacteriuria and gram negative rod bacteremia in abacteriuric patients with indwelling catheters. May be used orally to treat hepatic encephalopathy, as a perioperative prophylactic agent, and as an adjunct to fluid and electrolyte replacement in the treatment of diarrhea caused to enteropathogenic E. coli (EPEC).

Associated Conditions
Associated Therapies
Pharmacodynamics

Neomycin is an aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.

Mechanism of action

Aminoglycosides like neomycin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Specifically neomycin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.

TargetActionsOrganism
A30S ribosomal protein S12
inhibitor
Escherichia coli (strain K12)
A16S rRNA
inhibitor
Enteric bacteria and other eubacteria
UExtracellular calcium-sensing receptorNot AvailableHuman
Absorption

Poorly absorbed from the normal gastrointestinal tract. Although only approximately 3% of neomycin is absorbed through intact intestinal mucosa, significant amounts may be absorbed through ulcerated or denuded mucosa or if inflammation is present.

Volume of distribution
Not Available
Protein binding

Protein binding studies have shown that the degree of aminoglycoside protein binding is low and, depending upon the methods used for testing, may be between 0% and 30%.

Metabolism

Neomycin undergoes negligible biotransformation after parenteral administration.

Route of elimination

The small absorbed fraction is rapidly distributed in the tissues and is excreted by the kidney in keeping with the degree of kidney function.

Half life

2 to 3 hours

Clearance
Not Available
Toxicity

LD50 = 200 mg/kg (rat). Because of low absorption, it is unlikely that acute overdosage would occur with oral neomycin. However, prolonged administration could result in sufficient systemic drug levels to produce neurotoxicity, ototoxicity and/or nephrotoxicity. Nephrotoxicity occurs via drug accumulation in renal proximal tubular cells resulting in cellular damage. Tubular cells may regenerate despite continued exposure and nephrotoxicity is usually mild reversible. Neomycin is the most toxic aminoglycoside agent, which is thought to be due to its large number of cationic amino groups. Otoxocity occurs via drug accumulation in the endolymph and perilymph of the inner ear causing irreversible damage to hair cells in the cochlea or summit of ampullar cristae in the vestibular complex. High frequency hearing loss is followed by low frequency hearing loss. Further toxicity may cause retrograde degeneration of the auditory nerve. Vestibular toxicity may result in vertigo, nausea and vomiting, dizziness and loss of balance.

Affected organisms
  • Enteric bacteria and other eubacteria
  • Escherichia coli
  • Klebsiella
  • Enterobacter
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when Neomycin is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Neomycin is combined with (S)-Warfarin.
1,10-PhenanthrolineThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Neomycin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Neomycin is combined with 4-hydroxycoumarin.
AbacavirNeomycin may decrease the excretion rate of Abacavir which could result in a higher serum level.
AcarboseThe risk or severity of adverse effects can be increased when Neomycin is combined with Acarbose.
AceclofenacThe risk or severity of nephrotoxicity can be increased when Aceclofenac is combined with Neomycin.
AcemetacinThe risk or severity of nephrotoxicity can be increased when Acemetacin is combined with Neomycin.
AcenocoumarolThe risk or severity of bleeding can be increased when Neomycin is combined with Acenocoumarol.
AcetylcholineThe therapeutic efficacy of Acetylcholine can be decreased when used in combination with Neomycin.
Food Interactions
Not Available

References

Synthesis Reference

Jaehoon Yu, Jongkook Lee, Miyun Kwon, Ae Pae, Hun Koh, "Heterodimeric conjugates of neomycin-oxazolidinone, their preparation and their use." U.S. Patent US20050222055, issued October 06, 2005.

US20050222055
General References
Not Available
External Links
KEGG Drug
D08260
KEGG Compound
C00384
PubChem Substance
46505525
ChEBI
7507
Therapeutic Targets Database
DAP000036
PharmGKB
PA450608
HET
CNY
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Neomycin
ATC Codes
J01GB05 — NeomycinA07AA51 — Neomycin, combinationsS03AA01 — NeomycinB05CA09 — NeomycinS01AA03 — NeomycinD06AX04 — NeomycinA07AA01 — NeomycinS02AA07 — NeomycinR02AB01 — NeomycinA01AB08 — Neomycin
AHFS Codes
  • 08:12.02 — Aminoglycosides
  • 84:04.04 — Antibiotics
MSDS
Download (72.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceAtopic Dermatitis (AD)1
0Enrolling by InvitationBasic ScienceDietary Modifications / Nutrition1
0RecruitingSupportive CareDiverticulitis / Inflammatory Bowel Diseases (IBD) / Neoplasms, Colorectal / Surgical Site Infections1
0RecruitingTreatmentOsteomyelitis1
1CompletedNot AvailableNeoplasms1
1CompletedTreatmentPlasma Cell Myeloma1
1CompletedTreatmentSystemic Infections1
1RecruitingTreatmentRetinoblastoma1
1RecruitingTreatmentMinor burns1
1, 2WithdrawnSupportive CareDysbiosis / Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) / Inflammatory Reaction1
2Active Not RecruitingTreatmentIntestinal Colonization With Multidrug-resistant Bacteria1
2CompletedTreatmentPre-Diabetic1
2Not Yet RecruitingPreventionLeak, Anastomotic / Rectal Carcinoma1
2RecruitingTreatmentAppendicitis1
2RecruitingTreatmentBacteremia / Chronic Lung Disease of Prematurity / Chronic Lung Diseases / Ileal perforation / Intraventricular Hemorrhage / Necrotizing Enterocolitis / Periventricular Leukomalacia / Retinopathy of Prematurity1
2RecruitingTreatmentCrohn's Disease (CD)2
2RecruitingTreatmentInfection NOS / Sepsis / Severe Sepsis / Shock, Septic1
2Unknown StatusTreatmentPediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections1
2, 3Not Yet RecruitingTreatmentSocial Stress1
2, 3RecruitingTreatmentSepsis1
2, 3Unknown StatusPreventionBacteremia / Bacteremia Associated With Intravascular Line / Ventilator-associated Bacterial Pneumonia1
3Active Not RecruitingTreatmentUrinary Bladder, Overactive1
3CompletedPreventionFlu caused by Influenza1
3CompletedTreatmentCommunity Acquired Infections / Infections, Gram-Positive Bacterial / Pneumonia, Pneumococcal1
3CompletedTreatmentPeriodontitis1
3CompletedTreatmentSinusitis1
3RecruitingPreventionCritical Illness / Sepsis / Shock, Septic / Ventilator-associated Bacterial Pneumonia1
3RecruitingSupportive CareChronic Rhinosinusitis / Chronic Sinusitis - Ethmoidal Anterior / Chronic Sinusitis - Ethmoidal, Posterior / Chronic Sinusitis - Frontoethmoidal / Chronic Sinusitis, Ethmoidal / Chronic Sinusitis, Sphenoidal / Nasal Polyp - Posterior / Polyps, Nasal1
3RecruitingTreatmentAcute Otitis Externa1
3RecruitingTreatmentFractures, Open1
3TerminatedTreatmentBladder Cancers1
3TerminatedTreatmentSinusitis1
3Unknown StatusTreatmentAcute / Conjunctivitis, Bacterial1
3Unknown StatusTreatmentHordeolum1
3Unknown StatusTreatmentPneumonia1
4CompletedBasic ScienceFlu caused by Influenza1
4CompletedPreventionFlu caused by Influenza1
4CompletedPreventionPostoperative Infections2
4CompletedTreatmentAllergies1
4CompletedTreatmentFunctional Dyspepsia / Helicobacter Pylori / Peptic Ulcers1
4CompletedTreatmentHelicobacter Pylori Treatment Failure1
4CompletedTreatmentIndigestion / Peptic Ulcers1
4CompletedTreatmentPostoperative Infections1
4CompletedTreatmentPyelonephritis1
4CompletedTreatmentVertebral Osteomyelitis1
4Not Yet RecruitingTreatmentElective Colon Surgery1
4RecruitingBasic ScienceRabies Human1
4RecruitingPreventionAntibiotic Allergy / Antibiotic Side Effect / Eyelid Diseases / Eyelid; Wound / Infection, Postoperative Wound / Skin Cancer Face / Surgical Incision / Surgical Site Infections / Surgical Wound, Recent1
4RecruitingPreventionAntibiotic Prophylaxis / Pulmonary Tuberculosis (TB)1
4RecruitingTreatmentBacterial Vaginosis (BV) / Candidiasis infection1
4RecruitingTreatmentCystitis / Cystitis;Puerperium / Pyelonephritis1
4WithdrawnPreventionComplications; Breast Prosthesis, Infection or Inflammation1
Not AvailableActive Not RecruitingPreventionGeneral Surgery / Infection NOS1
Not AvailableCompletedNot AvailableAcute Cholecystitits1
Not AvailableCompletedNot AvailableDiverticulitis1
Not AvailableCompletedNot AvailablePatients Colonized by Klebsiella Pneumoniae1
Not AvailableCompletedNot AvailablePenicillin Allergy1
Not AvailableCompletedDiagnosticMinor burns1
Not AvailableCompletedOtherFlu caused by Influenza1
Not AvailableCompletedPreventionAnal Fistulas1
Not AvailableCompletedPreventionBiliary Atresia1
Not AvailableCompletedPreventionInfection NOS1
Not AvailableCompletedTreatmentAggressive Periodontitis, Generalized1
Not AvailableCompletedTreatmentBMI >30 kg/m2 / Diabetes Mellitus (DM)1
Not AvailableCompletedTreatmentConstipation-predominant Irritable Bowel Syndrome (IBS-C)1
Not AvailableCompletedTreatmentCorneal Diseases1
Not AvailableCompletedTreatmentDiverticulitis, Colonic1
Not AvailableCompletedTreatmentErectile Dysfunction (ED)1
Not AvailableCompletedTreatmentHospital Acquired Infections / Respiratory Tract Diseases1
Not AvailableCompletedTreatmentNasal Carriers of Staphylococcus Aureus1
Not AvailableCompletedTreatmentNeutropenia, Febrile1
Not AvailableCompletedTreatmentPeriodontitis1
Not AvailableCompletedTreatmentSnoring / Strep Throat1
Not AvailableCompletedTreatmentUlcerative Colitis (UC)1
Not AvailableEnrolling by InvitationNot AvailableMicrobial Colonization1
Not AvailableEnrolling by InvitationTreatmentAppendicitis Acute1
Not AvailableNot Yet RecruitingTreatmentAnal abscess / Anal Fistulas1
Not AvailableNot Yet RecruitingTreatmentUrinary Tract Infection in Pregnancy1
Not AvailableRecruitingNot AvailableMyelodysplastic Syndrome1
Not AvailableRecruitingBasic ScienceErythema Chronicum Migrans1
Not AvailableRecruitingDiagnosticInfection NOS1
Not AvailableRecruitingPreventionAsymptomatic Bacteriuria / Pyelonephritis1
Not AvailableRecruitingPreventionRectal Carcinoma1
Not AvailableRecruitingTreatmentLiver Cirrhosis / Small Intestinal Bacterial Overgrowth1
Not AvailableTerminatedTreatmentBacterial Keratitis / Fungal Keratitis1
Not AvailableUnknown StatusNot AvailableAsymptomatic Infections / Bacteriuria / Transplantation Infection / Urinary Tract Infections (UTIs)1
Not AvailableUnknown StatusPreventionInfection NOS1
Not AvailableUnknown StatusTreatmentHepatic Encephalopathy / Liver Cirrhosis / Portal Hypertension1
Not AvailableWithdrawnNot AvailableCystic Fibrosis (CF)1
Not AvailableWithdrawnTreatmentMinor burns1

Pharmacoeconomics

Manufacturers
  • X gen pharmaceuticals inc
  • Pharmacia and upjohn co
  • Pfizer laboratories div pfizer inc
  • Bristol myers squibb co
  • Lannett co inc
  • Eli lilly and co
  • Oman pharmaceutical products co llc
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
Packagers
  • Akorn Inc.
  • Amend
  • Bausch & Lomb Inc.
  • Dispensing Solutions
  • Draxis Specialty Pharmaceuticals Inc.
  • Hi Tech Pharmacal Co. Inc.
  • Major Pharmaceuticals
  • Murfreesboro Pharmaceutical Nursing Supply
  • Nucare Pharmaceuticals Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Southwood Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • X-Gen Pharmaceuticals
Dosage forms
FormRouteStrength
KitOral; Topical
Kit
KitTopical
PowderTopical
OintmentTopical3.5 mg/1g
CreamTopical5 mg/0.9g
SolutionAuricular (otic)
SuspensionTopical
OintmentOphthalmic; Topical
SuspensionOphthalmic
StickTopical
SolutionOral125 mg
TabletOral500 mg
OintmentTopical.5 %
SuspensionAuricular (otic); Ophthalmic
SolutionOral87.5 mg/5mL
LotionTopical
LiquidAuricular (otic); Ophthalmic
SolutionIrrigation
Solution / dropsOphthalmic
Solution / dropsAuricular (otic)
Suspension / dropsAuricular (otic)
Suspension / dropsOphthalmic
TabletOral350 mg/1
TabletOral500 mg/1
SolutionAuricular (otic); Ophthalmic
IrrigantIrrigation
SolutionUrethral
OintmentOphthalmic
LiquidOphthalmic
GelTopical
Solution / dropsAuricular (otic); Ophthalmic
SuspensionAuricular (otic)
OintmentTopical3.5 mg/57g
OintmentRectal
SuppositoryRectal
SolutionOphthalmic
CreamTopical
OintmentTopical
Prices
Unit descriptionCostUnit
Neomycin Sulfate 500 mg tablet1.39USD tablet
Neomycin 500 mg tablet1.25USD tablet
Neomycin sulfate powder0.84USD g
Neo-fradin 125 mg/5 ml soln0.12USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)6 mg/mL (as sulfate form)Not Available
logP-7.8Not Available
Predicted Properties
Not Available
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8617
Blood Brain Barrier-0.9659
Caco-2 permeable-0.7502
P-glycoprotein substrateNon-substrate0.5164
P-glycoprotein inhibitor INon-inhibitor0.8023
P-glycoprotein inhibitor IINon-inhibitor0.8764
Renal organic cation transporterNon-inhibitor0.7886
CYP450 2C9 substrateNon-substrate0.8231
CYP450 2D6 substrateNon-substrate0.8041
CYP450 3A4 substrateNon-substrate0.6473
CYP450 1A2 substrateNon-inhibitor0.9157
CYP450 2C9 inhibitorNon-inhibitor0.9147
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9034
CYP450 3A4 inhibitorNon-inhibitor0.9471
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8446
Ames testNon AMES toxic0.6934
CarcinogenicityNon-carcinogens0.9505
BiodegradationNot ready biodegradable0.8587
Rat acute toxicity1.4850 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9728
hERG inhibition (predictor II)Non-inhibitor0.81
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Trna binding
Specific Function
With S4 and S5 plays an important role in translational accuracy.Interacts with and stabilizes bases of the 16S rRNA that are involved in tRNA selection in the A site and with the mRNA backbone. Lo...
Gene Name
rpsL
Uniprot ID
P0A7S3
Uniprot Name
30S ribosomal protein S12
Molecular Weight
13736.995 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Gill AE, Amyes SG: The contribution of a novel ribosomal S12 mutation to aminoglycoside resistance of Escherichia coli mutants. J Chemother. 2004 Aug;16(4):347-9. [PubMed:15332709]
  4. Eisenstein BI, Beachey EH, Ofek I: Influence of sublethal concentrations of antibiotics on the expression of the mannose-specific ligand of Escherichia coli. Infect Immun. 1980 Apr;28(1):154-9. [PubMed:6103875]
2. 16S rRNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
Yes
Actions
Inhibitor
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Roy U, Nair D: Biodiversity of organotin resistant Pseudomonas from west coast of India. Ecotoxicology. 2007 Mar;16(2):253-61. Epub 2006 Nov 28. [PubMed:17131180]
  4. Wachino J, Shibayama K, Kurokawa H, Kimura K, Yamane K, Suzuki S, Shibata N, Ike Y, Arakawa Y: Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides. Antimicrob Agents Chemother. 2007 Dec;51(12):4401-9. Epub 2007 Sep 17. [PubMed:17875999]
  5. Brown JM, Cowley KD, Manninen KI, McNeil MM: Phenotypic and molecular epidemiologic evaluation of a Nocardia farcinica mastitis epizootic. Vet Microbiol. 2007 Nov 15;125(1-2):66-72. Epub 2007 May 6. [PubMed:17553640]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
Senses changes in the extracellular concentration of calcium ions. The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system.
Gene Name
CASR
Uniprot ID
P41180
Uniprot Name
Extracellular calcium-sensing receptor
Molecular Weight
120672.385 Da
References
  1. Molostvov G, James S, Fletcher S, Bennett J, Lehnert H, Bland R, Zehnder D: Extracellular calcium-sensing receptor is functionally expressed in human artery. Am J Physiol Renal Physiol. 2007 Sep;293(3):F946-55. Epub 2007 May 30. [PubMed:17537980]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2018 13:38